Love, S., Kerr, R., Segelov, E., Johnstone, E., Falcon, B., Hewett, P., . . . Kerr, D. (2016). Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): An open-label, randomised phase 3 trial. Lancet.
Citação norma ChicagoLove, S., et al. Adjuvant Capecitabine Plus Bevacizumab Versus Capecitabine Alone in Patients with Colorectal Cancer (QUASAR 2): An Open-label, Randomised Phase 3 Trial. Lancet, 2016.
Citação norma MLALove, S., et al. Adjuvant Capecitabine Plus Bevacizumab Versus Capecitabine Alone in Patients with Colorectal Cancer (QUASAR 2): An Open-label, Randomised Phase 3 Trial. Lancet, 2016.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.